CS
INO icon

Credit Suisse’s Inovio Pharmaceuticals INO Stock Holding History

Credit Suisse’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,583
Closed -$732K – 4468
2021
Q2 		$732K Buy
6,583
+2,183
+50% +$210K ﹤0.01% 3600
2021
Q1 		$490K Buy
+4,400
New +$579K ﹤0.01% 3780

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Credit Suisse's INO Position: Q1 2024 in Review

Credit Suisse sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 2,938 shares — an estimated $18K sold.

Credit Suisse first reported a position in INO in Q4 2013 and held it in 41 quarters. The position peaked at $8.39M in Q2 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Credit Suisse reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Credit Suisse sold 2,938 Inovio Pharmaceuticals shares in Q1 2024, an estimated $18K.
  • Credit Suisse first reported a position in Inovio Pharmaceuticals in Q4 2013 and held it in 41 quarters.
  • Credit Suisse's Inovio Pharmaceuticals position peaked at $8.39M in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.